Jordan R. Hansford, MD, discusses health-related quality-of-life outcomes with tovorafenib in pediatric patients with BRAF-altered low-grade glioma.
Jordan Hansford, MD
Advertisement
Articles by Jordan Hansford, MD
Jordan Hansford, MD, discusses the phase 2 FIREFLY-1 trial, which is investigating the pan-RAF inhibitor tovorafenib (DAY101) in children and young adults with low-grade glioma.
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
Epcoritamab Significantly Improves PFS Vs Chemoimmunotherapy in R/R Large B-Cell Lymphoma
2
AJ1-11095 Shows Spleen Responses and Symptom Improvement in Post–Type I JAK Inhibitor Myelofibrosis
3
Ziftomenib Plus 7+3 Elicits Durable Responses in Newly Diagnosed NPM1-Mutant and KMT2A-Rearranged AML
4
Fixed-Duration Pirtobrutinib/Venetoclax/Rituximab Drives PFS Benefit in R/R CLL
5